12 October 2016AmericasSandra Kuzmich and Russell Garman
Life Technologies v Promega: the long tentacles of infringement
After hearing three patent cases in its last term, the US Supreme Court agreed in June to take on another: Life Technologies et al v Promega et al. The Supreme Court’s focus will be on the meaning of a particular phrase—“substantial portion”—that appears in 35 USC §271(f)(1). This section of the patent statute governs infringement in circumstances where components from the US are shipped abroad for inclusion in a combination that would have infringed a patent had the combination been manufactured in the US.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
7 May 2026 A California judge has denied Corcept’s bid to dismiss the lawsuit over its drug for a rare hormonal disorder, allowing the litigation to proceed on all core counts.
5 May 2026 J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.
4 May 2026 LSIPR's senior reporter Marisa Woutersen speaks with Ben Doranz of Integral Molecular, fresh from the stage at LSPN Boston after speaking at a panel session on challenges in antibody patent protection.